Cognitive effects of carisbamate in randomized, placebo-controlled, healthy-volunteer, multidose studies

► Carisbamate is a novel drug in development for treatment of seizures and neuropathic pain. ► Three controlled, multiple-dose, phase I crossover studies were conducted. ► Cognitive effects were assessed in healthy volunteers treated for 5-9 days. ► No clinically significant adverse cognitive effects were observed at doses < 1000 mg/day. ► Effects were mild to modest at the higher doses tested.